Sanofi (SNY)

Sanofi (SNY)

Postby winston » Wed Oct 05, 2016 7:21 am

not vested

Singapore approves use of world's first dengue vaccine

BY LINETTE LAI

SINGAPORE: The Health Sciences Authority (HSA) has approved the world's first dengue vaccine Dengvaxia for use in Singapore following a seven-month expedited review of the potential benefits and risks.

It will be made commercially available in several months' time.

Manufacturers Sanofi has not yet said how much it will cost, although its global medical affairs head Dr Ng Su-Peing has said that the company's goal is to make the vaccine "as commercially accessible as possible".


Studies have shown that overall, the vaccine is effective at reducing dengue by 60%, and reducing severe dengue by 84%.


The risk of hospitalisation from dengue was reduced in those above 12 years old but also showed that the vaccine was not very effective in those aged above 45.


The vaccine was also 81% effective in people who had already had a dengue infection previously, compared to 38% in those who had never had the virus.


The Health Ministry does not recommend rolling out this dengue vacine as a national programme as it "would not be a clinically and cost-effective means to tackling dengue infection in Singapore".

This means that subsidies and Medisave cannot be used to pay for vaccination.


The vaccine was launched late in 2015 and is currently approved for use in nine other countries, including Indonesia and the Philippines.


Source: The Star



http://www.thestar.com.my/news/regional ... e-vaccine/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Oct 05, 2016 7:27 am

not vested

Sanofi to Seek U.S. Approval for First Dengue Vaccine in Months

by James Paton

Vaccine has been cleared in 11 nations including Thailand
Drugmaker expects to launch vaccine in Indonesia, Costa Rica

U.S. approval would provide a boost to the vaccine’s sales, which were just 1 million euros ($1.1 million) in the second quarter. Dengvaxia probably won’t meet its targets for the year due to economic and political volatility in Latin America, the Paris-based company said in July.

Analysts had previously anticipated about 200 million euros in sales for 2016. The vaccine is forecast by analysts to generate about $840 million in sales in 2020 and about $1 billion in 2025.


Dengvaxia is the world’s first dengue vaccine, developed over two decades at a cost of 1.5 billion euros. Dengue has spread quickly in recent years, with an estimated 390 million infections each year.


Source: Bloomberg

http://www.bloomberg.com/news/articles/ ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Oct 05, 2016 7:30 am

not vested

A stalled growth engine

by Brian Feroldi

French pharma giant Sanofi (NYSE:SNY) hasn't given its investors much reason to cheer over the past few years.

This company has relied heavily on uber-successful drugs such as Lantus and Plavix to generate growth, but sales of both are falling because of pricing pressure and competitive launches.

In turn, the company's shares have lost nearly a quarter of their value over the past three years, badly underperforming the S&P 500.

In response to the weak performance, Sanofi's board brought in a new leader named Olivier Brandicourt and tasked him with getting the company back on track. However, given Sanofi's size and product portfolio, that won't be easy.

Brandicourt attempted to appease Wall Street by laying out his five-year vision. His plan centers on the successful launches of six new blockbuster drugs, which he believes will reverse the revenue decline. If everything goes according to plan, then sales will grow by 3% to 4% annualized between now and 2020.

While I always appreciate it when a company lays out a long-term plan, I have a hard time getting excited about low-single-digit revenue growth. That's especially true considering Sanofi is banking on all of those new product launches to help it hit its numbers. What happens if one of them turns out to be a dud?

Sanofi may not be the worst investment in healthcare, but why bother owning this stock when faster-growing giants can be purchased just as easily? For that reason, I plan on avoiding Sanofi's stock until it turns these promises into a reality.

Source: Motley Fool
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Oct 05, 2016 7:38 am

not vested

Regeneron, Sanofi Report Drug Results (REGN, SNY)

By Shobhit Seth

October 3, 2016

The companies announced detailed results of a Phase III study evaluating Dupixent for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis.


An estimated 2% of adults and up to 20% of children in the United States are affected by the disease. The majority of these cases are mild or moderately severe.


“Dupixent to cost up to $30,000 a year and to capture eventual annual sales of more than $5 billion”


Source: Investopedia

http://www.investopedia.com/news/regene ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 7:05 pm

If You Own Just One Pharma Stock, Make It This

By MICHAEL A. ROBINSON

This company has one big drug coming to market in coming months, and it's expected to see $3 billion in annual sales by 2020.


Sanofi has 44 drugs in its pipeline and a whopping 13 in phase 3 trials.


This year Sanofi is set to release a new eczema drug, Dupixent. The price tag is a hefty $37,000 a year.

Dupixent is for the most difficult and painful cases of eczema, and it is doesn't have the cancerous side effects similar treatments for lesser forms of eczema carry with them.

But Sanofi wised up and did the work with the PBMs and insurance companies this time around.

What's more, Dupixent is the only drug that does what it does, which saves it from direct competition.


China is already Sanofi's third-largest market after the Unites States and, of course, France.


Diabetes drug Lantus was a major revenue source for Sanofi, but it came off-patent in 2015. But diabetes is rising in Asia, and Sanofi can sell the drug without as much competition


Eloxatin is used to treat colorectal cancer in the West, but Sanofi has re-engineered it and tested it to treat liver cancer in China.


It plans to launch more than 10 drugs in China by 2020.


The No. 5 drugmaker in the world


Source: Money Morning

https://moneymorning.com/2017/04/26/if- ... e-it-this/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 7:12 pm

FDA approves new eczema drug Dupixent

March 28, 2017

The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).

https://www.fda.gov/newsevents/newsroom ... 549078.htm
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 7:47 pm

Sanofi Genzyme hit with patent lawsuit over new eczema drug

by Max Stendahl

Source: American City Business Journals

https://moneymorning.com/2017/04/26/if- ... e-it-this/
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 7:58 pm

5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

It has a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and central nervous system disorders, among others.

Products like Toujeo(diabetes), Aubagio and Lemtrada(multiple sclerosis) have been doing well and the trend is likely to continue.

Importantly, Dupixent (dupilumab) was approved last month for the treatment of atopic dermatitis in the U.S. while the regulatory application for the same indication is under review in the EU.

Dupixent is also being evaluated for the treatment of asthma and nasal polyposis in phase III studies.

An important pipeline candidate is Kevzara (sarilumab), which was approved in Canada in Feb 2017 while in the U.S., the regulatory application is expected to be re-submitted to the FDA this year. The regulatory application in the EU was submitted in Jul 2016.

Soliqua, a once-daily titratable fixed-ratio combination of Lantus and Lyxumia, was launched in the U.S. in Jan 2017 and is expected to be launched in Europe later this year.

Other phase III candidates include sotagliflozin (SGLT-1 and SGLT-2 inhibitor for diabetes) and atuximab (multiple myeloma).


Sanofi faces its share of challenges such as generic competition for many drugs including its blockbuster drug, Plavix and slower-than-expected uptake of new products like Praluent. Also, the outlook for its Diabetes franchise is bleak.


Source: Zacks Equity Research

https://finance.yahoo.com/news/5-reason ... 12285.html
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 7:58 pm

5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

It has a presence in several therapeutic areas including cardiovascular diseases, diabetes, oncology, and central nervous system disorders, among others.

Products like Toujeo(diabetes), Aubagio and Lemtrada(multiple sclerosis) have been doing well and the trend is likely to continue.

Importantly, Dupixent (dupilumab) was approved last month for the treatment of atopic dermatitis in the U.S. while the regulatory application for the same indication is under review in the EU.

Dupixent is also being evaluated for the treatment of asthma and nasal polyposis in phase III studies.

An important pipeline candidate is Kevzara (sarilumab), which was approved in Canada in Feb 2017 while in the U.S., the regulatory application is expected to be re-submitted to the FDA this year. The regulatory application in the EU was submitted in Jul 2016.

Soliqua, a once-daily titratable fixed-ratio combination of Lantus and Lyxumia, was launched in the U.S. in Jan 2017 and is expected to be launched in Europe later this year.

Other phase III candidates include sotagliflozin (SGLT-1 and SGLT-2 inhibitor for diabetes) and atuximab (multiple myeloma).


Sanofi faces its share of challenges such as generic competition for many drugs including its blockbuster drug, Plavix and slower-than-expected uptake of new products like Praluent. Also, the outlook for its Diabetes franchise is bleak.


Source: Zacks Equity Research

https://finance.yahoo.com/news/5-reason ... 12285.html
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Re: Sanofi (SNY)

Postby winston » Wed Apr 26, 2017 8:02 pm

not vested

April 7, 2017

Sanofi Downgraded at HSBC Securities

by Amanda Schiavo

The downgrade comes as the firm sees valuation risk and the possibility of intensifying pricing pressure in the U.S.


Source: The Street

https://www.thestreet.com/story/1407836 ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 104534
Joined: Wed May 07, 2008 9:28 am

Next

Return to S to Z

Who is online

Users browsing this forum: No registered users and 2 guests

cron